AU2017300965B2 - Biofusion proteins as anti-malaria vaccines - Google Patents

Biofusion proteins as anti-malaria vaccines Download PDF

Info

Publication number
AU2017300965B2
AU2017300965B2 AU2017300965A AU2017300965A AU2017300965B2 AU 2017300965 B2 AU2017300965 B2 AU 2017300965B2 AU 2017300965 A AU2017300965 A AU 2017300965A AU 2017300965 A AU2017300965 A AU 2017300965A AU 2017300965 B2 AU2017300965 B2 AU 2017300965B2
Authority
AU
Australia
Prior art keywords
glu
lys
asn
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017300965A
Other languages
English (en)
Other versions
AU2017300965A1 (en
Inventor
Pierre Druilhe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vac4all Pte Ltd
Original Assignee
Vac4all Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vac4all Pte Ltd filed Critical Vac4all Pte Ltd
Publication of AU2017300965A1 publication Critical patent/AU2017300965A1/en
Application granted granted Critical
Publication of AU2017300965B2 publication Critical patent/AU2017300965B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017300965A 2016-07-21 2017-07-21 Biofusion proteins as anti-malaria vaccines Active AU2017300965B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16180544.5 2016-07-21
EP16180544 2016-07-21
PCT/SG2017/050369 WO2018017020A1 (en) 2016-07-21 2017-07-21 Biofusion proteins as anti-malaria vaccines

Publications (2)

Publication Number Publication Date
AU2017300965A1 AU2017300965A1 (en) 2019-02-07
AU2017300965B2 true AU2017300965B2 (en) 2024-09-12

Family

ID=56550732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017300965A Active AU2017300965B2 (en) 2016-07-21 2017-07-21 Biofusion proteins as anti-malaria vaccines

Country Status (10)

Country Link
US (2) US20210038706A1 (enExample)
EP (2) EP4147715A1 (enExample)
JP (2) JP2019526274A (enExample)
KR (2) KR20190090775A (enExample)
CN (1) CN109963586B (enExample)
AU (1) AU2017300965B2 (enExample)
BR (1) BR112019001115A2 (enExample)
CA (1) CA3031399A1 (enExample)
TW (1) TWI780058B (enExample)
WO (1) WO2018017020A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3104833A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
WO2020033398A1 (en) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating atii cell-dependent lung diseases
CA3119865A1 (en) * 2018-11-23 2020-05-28 Strike Pharma Ab Bi-specific conjugates
US11052144B2 (en) 2019-04-25 2021-07-06 Dcprime B.V. Methods of tumor vaccination
NL2023863B1 (en) * 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof
CN111135290A (zh) * 2020-01-16 2020-05-12 定山石生物科技(北京)有限公司 一种用于激活人体免疫细胞的多肽试剂
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
BE1029148B1 (fr) * 2021-02-26 2022-09-26 Curavac Europe Vaccin pour un traitement therapeutique ou prophylactique de la myastenie grave
CN118207228B (zh) * 2024-03-21 2025-03-14 中国科学院上海免疫与感染研究所 一种防治结合的多时期双靶点串联疟疾mRNA疫苗
CN120209159B (zh) * 2025-02-24 2026-08-04 南京澄实生物医药科技有限公司 一种预防疟原虫感染的融合蛋白和免疫原性组合物及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050077A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
SI2336147T1 (sl) * 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
KR101839496B1 (ko) * 2011-06-01 2018-03-19 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
CA2903716C (en) * 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides

Also Published As

Publication number Publication date
TWI780058B (zh) 2022-10-11
CN109963586B (zh) 2023-11-03
EP4147715A1 (en) 2023-03-15
AU2017300965A1 (en) 2019-02-07
US20210038706A1 (en) 2021-02-11
JP2022116169A (ja) 2022-08-09
JP2019526274A (ja) 2019-09-19
TW201803907A (zh) 2018-02-01
US20220409712A1 (en) 2022-12-29
EP3487526B1 (en) 2022-07-06
BR112019001115A2 (pt) 2019-06-25
WO2018017020A1 (en) 2018-01-25
CN109963586A (zh) 2019-07-02
EP3487526A1 (en) 2019-05-29
JP7579298B2 (ja) 2024-11-07
KR20240154691A (ko) 2024-10-25
KR20190090775A (ko) 2019-08-02
CA3031399A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
AU2017205270B2 (en) Therapeutic anticancer neoepitope vaccine
US8470560B2 (en) CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
JP7121443B2 (ja) 多用途性且つ効率的な遺伝子発現のためのｒｎａレプリコン
US5856187A (en) Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
AU2020411873B2 (en) Mutant RSV F protein and use thereof
JP5932647B2 (ja) エキソソームに結合した目的のポリペプチドの分泌を可能にする新規キメラポリヌクレオチド及びポリペプチド、並びにその使用
US20220409712A1 (en) Biofusion proteins as anti-malaria vaccines
AU2017260323B2 (en) Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
US7811576B2 (en) Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
KR101871530B1 (ko) 말라리아 치료 및 예방
CA2508957A1 (en) Yeast-based vaccines as immunotherapy
AU2022207569A9 (en) Stable preparation of human papillomavirus virus-like particle vaccine
AU2021351255A9 (en) Sars-cov-2 protein-derived peptide and vaccine containing same
US7144712B2 (en) Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CA2066940C (en) Canine coronavirus subunit vaccine
CA2273199A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
DK1802340T3 (en) A combination of recombinant mycobacteria and a biologically active agent as a vaccine
Wu et al. Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium falciparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C
WO2023018817A1 (en) Truncated influenza neuraminidase and methods of using the same
US20110150932A1 (en) Constructing a DNA Chimera for Vaccine Development Against Leishmaniasis and Tuberculosis
CA2262500C (en) Measles virus mutant antigen and gene coding for the same
CA2365451A1 (en) Nucleic acid molecule comprising a nucleic acid sequence coding for a hemocyanin
AU2021418202A9 (en) SARS-CoV-2 PROTEIN-DERIVED PEPTIDE AND VACCINE CONTAINING SAME
WO2004106365A2 (en) Modulatory peptide motifs for inducing th1 or th2 immune response
CA2245002A1 (en) Malaria vaccine based upon the addition of a msa1 peptide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)